Sb27: Clinical Trials

30 trials of Sb27, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

13 recruiting, 12 active not recruiting, 3 not yet recruiting, 1 completed. 30 Phase 2, 5 Phase 1, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 230Recruiting 13, Active not recruiting 12, Not yet recruiting 3, Completed 1, Suspended 1
Phase 15Active not recruiting 3, Recruiting 1, Suspended 1
Phase 32Not yet recruiting 2

Follow Sb27: new trials by email Literature Review of Sb27 trials Research Report on Sb27

Trials (filtered) newest first · largest first

All 30 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer
Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma
Phase 2 / Phase 3Not yet recruitingECOG-ACRIN Cancer Research Group3362027-01-112026-08-14
Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment
Biospecimen Collection, Brentuximab Vedotin, Computed Tomography - Classic Hodgkin Lymphoma
Phase 2RecruitingCity of Hope Medical Center232027-01-012026-11-12
Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma
3-Dimensional Conformal Radiation Therapy, Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection - Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
Phase 2 / Phase 3Not yet recruitingNational Cancer Institute (NCI)3742026-12-042026-07-08
CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery to Improve Treatment of Melanoma Brain Metastases
Emavusertib, Pembrolizumab, Stereotactic Radiosurgery - Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma
Phase 1 / Phase 2SuspendedMayo Clinic232026-11-302026-10-20
Proton Spatially Fractionated Radiotherapy or Photon Stereotactic Body Radiotherapy in Combination With Pembrolizumab Before Surgery for the Treatment of Locally Advanced and Radiation-Naive Locoregionally Recurrent Oral Cavity Cancer, OSPRI Trial
Biopsy Procedure, Biospecimen Collection, Computed Tomography - Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Recurrent Oral Cavity Squamous Cell Carcinoma
Phase 2RecruitingMayo Clinic302026-11-042026-11-06
Induction Chemoimmunotherapy to Prevent Laryngectomy in Advanced Laryngeal Cancer and Hypopharyngeal Cancer
Biospecimen Collection, Carboplatin, Chemotherapy - Advanced Laryngeal Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma
Phase 2Not yet recruitingMayo Clinic502026-11-012026-11-09
Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer
Quemliclustat, Biospecimen Collection, Computed Tomography - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma
Phase 1 / Phase 2RecruitingFred Hutchinson Cancer Center272026-10-202026-10-22
GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma
Biospecimen Collection, Bispecific CD80-lgG4Fc-IL-2v Fusion Protein GI-102, Computed Tomography - Glioblastoma, IDH-Wildtype, Progressive Astrocytoma, IDH-Mutant, Grade 4
Phase 2RecruitingMayo Clinic362026-08-032026-10-30
Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery
Biospecimen Collection, Clostridium butyricum CBM588 Strain, Computed Tomography - Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma
Phase 2RecruitingCity of Hope Medical Center622026-07-082026-10-19
GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer
Anti-CFH Monoclonal Antibody GT103, Biopsy Procedure, Biospecimen Collection - Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma
Phase 2RecruitingRoswell Park Cancer Institute282026-04-012026-08-19
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
Biospecimen Collection, Computed Tomography, Cystoscopy - Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8
Phase 2RecruitingNational Cancer Institute (NCI)1112025-11-252026-11-03
Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial
Biospecimen Collection, Hormone Therapy, Pembrolizumab - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Phase 2RecruitingM.D. Anderson Cancer Center1202025-10-092026-11-03
Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC
Biospecimen Collection, Breast Biopsy Procedure, Carboplatin - Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Phase 2RecruitingVandana Abramson512025-09-092025-10-30
Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers
Best Practice, Biospecimen Collection, Central Venous Cannula Insertion - Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma
Phase 2RecruitingMayo Clinic702025-08-012026-05-08
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
Biospecimen Collection, Cisplatin, Computed Tomography - Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma
Phase 2RecruitingNational Cancer Institute (NCI)1602025-06-032026-11-09
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
Avelumab, Axitinib, Biospecimen Collection - Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8
Phase 2RecruitingNRG Oncology2402023-02-012026-10-23
Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
Biopsy Procedure, Biospecimen Collection, Computed Tomography - Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma
Phase 2Active not recruitingNational Cancer Institute (NCI)522022-07-262026-11-12
A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma
Biopsy Procedure, Biospecimen Collection, Computed Tomography - Clinical Stage III Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary
Phase 2Active not recruitingNational Cancer Institute (NCI)602021-10-152026-11-12
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
Carboplatin, Cisplatin, Computed Tomography - Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma
Phase 2RecruitingNational Cancer Institute (NCI)1882021-04-272026-11-12
Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer
Berzosertib, Biospecimen Collection, Carboplatin - Lung Non-Small Cell Squamous Carcinoma, Stage IV Lung Cancer AJCC v8
Phase 1 / Phase 2Active not recruitingNational Cancer Institute (NCI)122021-04-142026-11-13

Showing 20 of 30. Sign in to see all of them.

Conditions studied

Urinary Bladder Neoplasms (6)  ·  Squamous Cell Carcinoma of Head and Neck (4)  ·  Melanoma (3)  ·  Carcinoma, Renal Cell (2)  ·  Laryngeal Neoplasms (2)  ·  Leukemia, Myeloid, Acute (2)  ·  Lung Neoplasms (2)  ·  Ureteral Neoplasms (2)  ·  Astrocytoma (1)  ·  Brain Neoplasms (1)  ·  Carcinoma (1)  ·  Carcinoma, Merkel Cell (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Carcinoma, Transitional Cell (1)  ·  Cholangiocarcinoma (1)

Sponsors

National Cancer Institute (NCI) (17)  ·  Mayo Clinic (5)  ·  City of Hope Medical Center (2)  ·  ECOG-ACRIN Cancer Research Group (1)  ·  Fred Hutchinson Cancer Center (1)  ·  M.D. Anderson Cancer Center (1)  ·  NRG Oncology (1)  ·  Roswell Park Cancer Institute (1)  ·  Vandana Abramson (1)

Countries

United States (28)  ·  Canada (4)  ·  Australia (1)  ·  Guam (1)  ·  Ireland (1)  ·  Puerto Rico (1)

Top investigators

Amer M Zeidan (2)  ·  Aaron S Mansfield (1)  ·  Ahmad Tarhini (1)  ·  Bently Doonan, MD, MS (1)  ·  Brian C Baumann (1)  ·  Dan P Zandberg (1)  ·  Daniel K. Ebner, MD, MPH (1)  ·  Deirdre J Cohen (1)  ·  Edwin H Yau (1)  ·  Jacob J. Orme, MD, PhD (1)  ·  Jacob S Thomas (1)  ·  Jason J Luke (1)  ·  Jessica M. Wilson, MD, PhD (1)  ·  Jian L Campian, MD, PhD (1)  ·  Kari L Kendra (1)

Results publications

PMID 36648215, PMID 36856617, PMID 37104746, PMID 40811146, PMID 40813711, PMID 41206673, PMID 41611998

NIH funding

U10CA180888 (5), U10CA180820 (4), P30CA033572 (2), U10CA180821 (2), U10CA180868 (2), UM1CA186689 (2), P30CA016672 (1), P30CA060553 (1), P30CA068485 (1), UM1CA186686 (1), UM1CA186690 (1), UM1CA186709 (1), UM1CA186717 (1)